The use of lumacaftor/ivacaftor to treat acute deterioration in paediatric cystic fibrosis

被引：3
|
作者：
Hammond, James A. [1 ]
Connett, Gary J. [1 ]
机构：
[1] Southampton Childrens Hosp, Southampton Biomed Res Ctr, Natl Inst Hlth Res, Tremona Rd, Southampton SO16 6YD, Hants, England
来源：
PAEDIATRIC RESPIRATORY REVIEWS | 2018年 / 27卷
关键词：
Cystic fibrosis; Lumacaftor; Ivacaftor; Paediatric; SEVERE LUNG-DISEASE; AGED; 6-11; YEARS; COMBINATION THERAPY; PHE508DEL CFTR; IN-VITRO; F508DEL-CFTR; INITIATION; IVACAFTOR; EFFICACY; MUTATION;
D O I：
10.1016/j.prrv.2018.05.008
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
Lumacaftor/ivacaftor is a precision medicine targeting the defective cystic fibrosis transmembrane regulator (CFTR) protein in cystic fibrosis (CF) patients homozygous for Phe508del genotype. Whilst there is evidence for efficacy in children aged 6-11 years who are stable with good lung function, there are little data about the use of this medication for children with acute deterioration in this age group. We describe the use of this drug to treat a child with an unusually severe exacerbation of CF lung disease and review the potential of lumacaftor/ivacaftor as a rescue therapy in the paediatric CF population. Crown Copyright (C) 2018 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：16 / 17
页数：2
相关论文
共 50 条
  • [41] Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients
    Katherine Kutney
    Shannon B Donnola
    Chris A Flask
    Rose Gubitosi-Klug
    MaryAnn O'Riordan
    Kimberly McBennett
    Thomas J Sferra
    Beth Kaminski
    World Journal of Hepatology, 2019, 11 (12) : 761 - 772
  • [42] Lumacaftor/ivacaftor-associated health stabilisation in adults with severe cystic fibrosis
    King, Susannah J.
    Keating, Dominic
    Williams, Elyssa
    Paul, Eldho
    Borg, Brigitte M.
    Finlayson, Felicity
    Button, Brenda M.
    Wilson, John W.
    Kotsimbos, Tom
    ERJ OPEN RESEARCH, 2021, 7 (01) : 1 - 10
  • [43] An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor
    Jennings, Mark T.
    Dezube, Rebecca
    Paranjape, Shruti
    West, Natalie E.
    Hong, Gina
    Braun, Andrew
    Grant, Jonathan
    Merlo, Christian A.
    Lechtzin, Noah
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2017, 14 (11) : 1662 - 1666
  • [44] CATAMENIAL HEMOPTYSIS IN CYSTIC FIBROSIS - FIXED BY HORMONAL THERAPY BUT UNMASKED BY LUMACAFTOR/IVACAFTOR
    Thaxton, A.
    West, N. E.
    PEDIATRIC PULMONOLOGY, 2017, 52 : S237 - S237
  • [45] Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis
    Hanafin, Patrick O.
    Sermet-Gaudelus, Isabelle
    Griese, Matthias
    Kappler, Matthias
    Ellemunter, Helmut
    Schwarz, Carsten
    Wilson, John
    Tan, Marsha
    Velkov, Tony
    Rao, Gauri G.
    Schneider-Futschik, Elena K.
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [46] Cystic Fibrosis: recent Studies - new Drugs In June, new Data for Ivacaftor and Lumacaftor/Ivacaftor were presented at the Conference of the European Cystic Fibrosis Society
    不详
    PADIATRIE UND PADOLOGIE, 2016, 51 (04): : 186 - +
  • [47] How Clinically Efficient Are Lumacaftor/Ivacaftor for Cystic Fibrosis Patients: An Updated Literature Review
    Perveen, Sumera
    Chaudhry, Muhammad Reza
    AlBabtain, Sarah
    Amreen, Sana
    Brar, Simrandeep K.
    Zeb, Mehwish
    Khan, Safeera
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (12)
  • [48] Real World Respiratory Effectiveness of Lumacaftor-Ivacaftor in Children with Cystic Fibrosis at Four Nemours Cystic Fibrosis Centers
    Greenawald, L.
    Shenoy, A. R.
    Peeke, K.
    Elidemir, O.
    Livingston, F. R.
    Schaeffer, D. A.
    Chidekel, A. S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [49] Effects of Lumacaftor/Ivacaftor on physical activity and exercise tolerance in three adults with cystic fibrosis
    Savi, Daniela
    Schiavetto, Stefano
    Simmonds, Nicholas J.
    Righelli, Dario
    Palange, Paolo
    JOURNAL OF CYSTIC FIBROSIS, 2019, 18 (03) : 420 - 424
  • [50] Real World Assessment of Patients with Cystic Fibrosis Treated with Lumacaftor-Ivacaftor and Transitioned to Tezacaftor-Ivacaftor
    Christmas, A.
    O'Hagan, A. R.
    Morton, R. L.
    Eid, N. S.
    Bickel, S. G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
12345